This legislation is designed to promote the production of generic drugs and biosimilars in the United States by offering financial incentives to manufacturers. Its primary goal is to enhance the availability of affordable medications, thereby improving public health and reducing overall healthcare costs. The bill introduces two main tax credits: a production credit and an investment credit.